

Tvac® tumor individualized precise combined immunotherapy

Guangzhou Runsheng Cell Pharmaceutical Technology Co., Ltd.

Company Profile

Guangzhou Runsheng Cell Pharmaceutical Technology Co., Ltd.

Focus on
Cell Medicine R & D and Clinical Transformation Research Biotechnology Enterprises

Established in	Located in	Built
September 2019	Guangdong Medical Valley	1500 F GMP Lab

The establishment is completed
Whole production chain platform (bio-information platform, vaccine platform, cell platform)

enterprise vision

- Focus on the development of new technologies for tumor cell therapy
- Finally, the tumor can be prevented, treated and recovered.

Obtain 10 patents and 5 software copyrights

National high-tech enterprises

innovative smes

China 's first cell combination therapy IND declaration unit

Team Introduction founder

The original intention of starting a business : it is the meaning of feeding back after success and fame, and also the compassion of those who practice medicine and help the world.

Ruan Runsheng

Doctor of Medicine, University of Zurich ; Professor, Department of Medicine, National University of Singapore ; Postdoctoral supervisor ; Expert in Tumor Immunology and Regenerative Medicine. Senior Fellow, Department of Medicine, National University of Singapore, Chief Fellow, Institute of Bioengineering and Nanotechnology, Science and Technology of Singapore, Member of the European Society of Oncology (ESMO). Professor Ruan Runsheng has been devoted to the research and development of cellular immunology for many years, and is the founder of Tvac ® tumor individualized precision combined immunotherapy technology. In 2019, Guangzhou Runsheng Cell Pharmaceutical Technology Co., Ltd.was founded with lifelong academic knowledge, research results and funds to return to China and start a business. It is committed to promoting the research and application of tumor immunotherapy in China, improving the current effect of tumor therapy in China, and cultivating high-precision talents in the field of tumor research and development.

★Doctor of Medicine, University of Zurich, Professor of Medicine, National University of Singapore, Postdoctoral Supervisor.
★ The Marquis ' Who 's Who Yearbook
★BARONS ' 500 Leaders for the New Century
★Member of the National Science Fellowship Evaluation Committee of the Singapore Science and Technology Authority
★ Xiamen 's ' Double Hundred ' entrepreneurial leading talents
★ Overseas Chinese Office of the State Council ' key overseas Chinese entrepreneurial team
★ Hundreds of enterprises in China Overseas Student Pioneer Park have the most entrepreneurial potential.
★Member of the First Scientific and Technological Innovation Committee of China Overseas Chinese Investment Enterprise Association

- **Published more than sixty articles in the international top weekly Nature, Cell, Science, etc.**

Source	Project	Duration	Amount(S $)	Approval date
Singapore Ministry of Education Academic Research Fund	Study on facial nerve regeneration	1993-1996	883,167.00	Jul. 1993
National Medical Research Council, Ministry of Health, Singapore	Study on the regeneration of inner ear villus cells	1996-1998	205,200.00	Apr. 1996
Singapore Ministry of Education Academic Research Fund	Study on inner ear regeneration	1998-2000	851,000.00	Oct. 1998
	Effect of growth factors on nerve regeneration	1999-2001	774,549.00	Jan. 1999
National Medical Research Council, Ministry of Health, Singapore	Gene transfection in the treatment of nervous deafness	2000-2001	882,300.00	Jun. 2000
	Study on nasopharyngeal carcinoma	2000-2002	167,500.00	Apr. 2000
Biomedical Research Committee of Singapore Science and Technology Bureau	Expansion of tumor antigen-specific CD8 cells in vitro	2002-2006	966,000.00	Jul. 2002

Technology Introduction

The cost is expected to be reduced by more than 80 %.

The new technical route reduces the cost and operation difficulty, and solves the pain point of tumor immunotherapy that is difficult to be clinically promoted by TIL cell therapy!

tumor vaccine **cells therapy**



Tvac® tumor individualized precision combined immunotherapy

It combines tumor therapeutic vaccine with cell therapy, and plays the role of active immunity and passive immunity at the same time, breaks through the heterogeneity of tumors and enhances the specificity and effectiveness of immune cell therapy.

The effectiveness of the personalized vaccine was verified by in vitro immunogenicity test and patient neoantigen-specific lethal immune cell test. The complementary advantages of various cutting-edge technologies ultimately make the initiation of tumor immunotherapy shorter, less toxic and side effects, stronger specificity, wider scope of application, and benefit as many patients as possible.

Tumor immune process-tumor specific antigen



Important causes of tumorigenesis:

The immune tolerance of tumors to the immune system makes the immune system lose the ability to recognize and remove tumors.

Tumor specific antigen:

Neoantigen, also known as tumor neoantigen, refers to a new antigen that is only expressed on the surface of a certain tumor cell and does not exist on normal cells.

RCMT

Individualized precise immunotherapy of Tvac ® tumor.

To achieve the prevention, treatment and rehabilitation of tumors.

Email：*ruanrs@gzrcmt.com*

Tel. *(020)3685 8614*